Mannose

Volurine Utilizes D-Mannose to Safely Prevent UTIs

Retrieved on: 
Wednesday, January 31, 2024
Mannose, Bacteria, Heart, System, Urinary tract infection, Urination, Escherichia coli, Risk, Infection, UTI, Health, Genetically modified bacteria, Woman, Dietary supplement

FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Urinary tract infections or UTIs are a common bacterial infection. Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly. Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.

Key Points: 
  • Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly.
  • Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.
  • One of these is D-mannose, a natural simple sugar that functions as the key ingredient in SYENVIT®'s UTI supplement Volurine .
  • It is becoming a popular natural alternative that is a safe, effective way to prevent UTIs without the need to wait for the signs of a painful infection to appear.

M6P Therapeutics Presents Promising Preclinical Data In Lysosomal Storage Disorders At The 19th Annual WORLDSymposium™ 2023

Retrieved on: 
Tuesday, February 21, 2023
Gaucher's disease, Glycogen storage disease, Mannose, Glycogen storage disease type II, Abstract, Q&A, Tissue, M6P, Cell, Research, Therapy, LSD, Gaucher, Pharmaceutical industry

ST. LOUIS, Mo., Feb. 21, 2023 (GLOBE NEWSWIRE) -- M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of promising preclinical data at the 19th Annual WORLDSymposium™, a research conference dedicated to lysosomal diseases being held in Orlando, FL, and virtually Feb. 22-26, 2023.

Key Points: 
  • ST. LOUIS, Mo., Feb. 21, 2023 (GLOBE NEWSWIRE) -- M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs), today announced the presentation of promising preclinical data at the 19th Annual WORLDSymposium™, a research conference dedicated to lysosomal diseases being held in Orlando, FL, and virtually Feb. 22-26, 2023.
  • In five poster presentations, including two Contemporary Forum presentations, M6P Therapeutics’ researchers report preclinical efficacy results for LSDs, including Gaucher disease and Pompe disease.
  • “We are thrilled with the continued development of our S1S3 phosphotransferase platform for producing lysosomal enzymes with high levels of mannose 6-phosphate to enable much better drug targeting and delivery of therapeutic lysosomal enzymes to all affected cells and tissues,” said Cuong Do, Chairman of M6P Therapeutics.
  • The abstracts will also be made available on the “ Publications ” section of M6PT’s corporate website following the presentations.

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Retrieved on: 
Thursday, January 5, 2023
Cancer, Patient, Mannose, Control, Degenerative disease, ADC, Safety, Neoplasm, Fine chemical, Vaccine, Duality

Under the terms of the agreement, Adcendo will license Duality's proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program in mesenchymal cancers.

Key Points: 
  • Under the terms of the agreement, Adcendo will license Duality's proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program in mesenchymal cancers.
  • Both parties are in discussions to expand the license agreement to cover additional targets selected by Adcendo.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very pleased to announce this agreement to leverage Duality's DITAC platform for our first-in-class uPARAP ADC program.
  • John Zhu, Chief Executive Officer of Duality, said: "Duality is dedicated to becoming a leading next-generation ADC company.

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Retrieved on: 
Thursday, January 5, 2023
Cancer, Patient, Mannose, Control, Degenerative disease, ADC, Safety, Neoplasm, Fine chemical, Vaccine, Duality

Under the terms of the agreement, Adcendo will license Duality's proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program in mesenchymal cancers.

Key Points: 
  • Under the terms of the agreement, Adcendo will license Duality's proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program in mesenchymal cancers.
  • Both parties are in discussions to expand the license agreement to cover additional targets selected by Adcendo.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very pleased to announce this agreement to leverage Duality's DITAC platform for our first-in-class uPARAP ADC program.
  • John Zhu, Chief Executive Officer of Duality, said: "Duality is dedicated to becoming a leading next-generation ADC company.

M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress

Retrieved on: 
Tuesday, October 11, 2022
Health, Other Science, General Health, Research, Science, Biotechnology, Congress, ESGCT, LSD, Therapy, Conference, Animal, Cell, Drug development, Gene, Publication, Glycogen storage disease, Tissue, Program, European Society of Gene and Cell Therapy, Technology, R, Gaucher's disease, Edinburgh International Conference Centre, Neuron, AAV, Phosphorylation, Metabolic disorder, Glycosphingolipid, CEO, A-DNA, CNS, Brain, Â, Mannose, GBA1, Central nervous system, M6P, Poster, Pharmaceutical industry, Fine chemical, Gaucher

The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.

Key Points: 
  • The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.
  • The data from this preclinical study illustrate the potential of our AAV-GBA-S1S3 gene therapy candidate for the treatment of Gaucher disease, including neuronopathic phenotypes, said Pawel Krysiak, President and CEO of M6P Therapeutics.
  • M012 is part of our pipeline of candidates leveraging a first-in-class co-expression S1S3 platform technology for the treatment of lysosomal storage disorders.
  • Gene therapy could be a potential therapeutic approach to treat all three types of Gaucher disease.

The Company Behind "FLO Vitamins" Enters Vaginal Health Space With New Science-Backed Collection Of Vaginal Probiotic And Urinary Tract Supplements

Retrieved on: 
Tuesday, September 13, 2022
Probiotic, VP, Time-invariant system, Health, FLO, Gaps, Mannose, Woman, Risk, FDA, Food, Urinary tract infection, Vagina, UTI, Digestion, MOTO, Metabolism, Maintenance, PMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Menopause, Instagram, Self-care, Solution, Bacteria, Collection, URO, Water, Birth control, Dietary supplement, Capsule

LOS ANGELES, Sept. 13, 2022 /PRNewswire/ -- Women's health brand O Positiv is entering the vaginal health space with its latest supplement collection URO, which launches today. The non-GMO, vegan and major-allergen free Vaginal Probiotic (URO VP) and Urinary Tract (URO UT) Capsules are intended to support overall vaginal balance, ultimately helping with vaginal and urinary tract health.

Key Points: 
  • LOS ANGELES, Sept. 13, 2022 /PRNewswire/ -- Women's health brand O Positiv is entering the vaginal health space with its latest supplement collection URO, which launches today.
  • The non-GMO, vegan and major-allergen free Vaginal Probiotic (URO VP) and Urinary Tract (URO UT) Capsules are intended to support overall vaginal balance, ultimately helping with vaginal and urinary tract health.
  • Urinary Tract Capsules (URO UT): An antibiotic-free solution that leverages clinically-studied Pacran Cranberry Extract, D-Mannose and Vitamin C to promote optimal urinary tract health.
  • URO UT's best-in-class ingredients work to help maintain healthy levels of bacteria in the urinary tract and promote urinary frequency.

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

M6P Therapeutics to Participate in Key Event Highlights at WORLDSymposium™ 2022 and Present Preclinical Data Across Multiple Lysosomal Diseases

Retrieved on: 
Wednesday, February 2, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, III, Therapy, Intellectual disability, MPS, Mannose, Central nervous system, Publication, Â, GAG, Urinary tract infection, Enzyme replacement therapy, Glycogen storage disease type II, Research, Disease, Degenerative disease, Hearing loss, PT, Q&A, Lysosomal storage disease, Innovation, LSD, Roscoe, 2021 Essex County Council election, Gaucher's disease, Glycogen storage disease, Pharmaceutical industry, Fertilizer, Platinum, Sanfilippo, Sanfilippo Syndrome Type B, Gaucher Disease, Pompe Disease, M6P Therapeutics, SANFILIPPO SYNDROME TYPE B, GAUCHER DISEASE, POMPE DISEASE, M6P THERAPEUTICS

Both the award and the recipients address spotlight Dr. Kornfelds decades of research on the role of mannose-6 phosphate (M6P) in lysosomal targeting and lysosomal enzyme trafficking.

Key Points: 
  • Both the award and the recipients address spotlight Dr. Kornfelds decades of research on the role of mannose-6 phosphate (M6P) in lysosomal targeting and lysosomal enzyme trafficking.
  • The 2022 e-Poster abstracts will be available beginning on Monday, Feb. 7, 2022, at 3:00pm PT (6:00pm ET).
  • 1:00pm PT Contemporary Forum Talk, Dr. Andrew Hedman, A novel S1S3 phosphotransferase co-expression gene therapy platform for lysosomal disorders
    5.
  • M6P Therapeutics (or M6PT) is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs).

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Retrieved on: 
Wednesday, December 1, 2021
University College Dublin, Cell, Company, GBM, Doctor of Philosophy, VP, SVP, DNA, Master of Science, Board, United States Air Force Scientific Advisory Board, Mannose, Glioblastoma, Genetics, Pharmacology, Prostate Cancer Foundation, Novo Holdings A/S, Cancer, University, CDO, Research, Seagen, ADC, Copenhagen, Osteosarcoma, II, Fred Hutchinson Cancer Research Center, Finsen Laboratory, CMC, Health Canada, Novo Nordisk, Soft-tissue sarcoma, Kinetics, FDA, Genmab, Brentuximab vedotin, Control, Drug discovery, Patient, CTO, Rigshospitalet, Biophysical chemistry, Industry, MAA, SAB, BLA, Program, Mesothelioma, EUR, Antibody, Science, Fine chemical, Pharmaceutical industry

In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).

Key Points: 
  • In addition, Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
  • Commenting on the appointments, Michael Pehl, Chief Executive Officer of Adcendo, said: "I am delighted to announce these appointments today as we build on our committed team at Adcendo.
  • "We are also extremely excited to have gained someone of Dennis' caliber to support Adcendo.
  • In addition to this program, Adcendo aims to build a pipeline of additional novel cancer targets ideally suited to ADC approaches.